Zilbrysq (▾ezalmad) is a medication indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults [1]. This includes patients with clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1].
What is Zilbrysq's mechanism of action?
Zilbrysq is a sphingosine 1-phosphate (S1P) receptor modulator [1]. It selectively binds to S1P subtypes 1, 3, 4, and 5 [1]. By binding to S1P receptors on lymphocytes, Zilbrysq inhibits lymphocyte migration from secondary lymphoid organs into the central nervous system (CNS) [1]. This action is believed to reduce the autoimmune attack on myelin and axons in MS [1].
How is Zilbrysq administered and dosed?
Zilbrysq is an oral medication taken once daily [1]. The recommended starting dose is 0.75 mg once daily for four days, followed by the target maintenance dose of 1.5 mg once daily [1]. Patients should be transitioned from other S1P receptor modulators to Zilbrysq according to recommended guidelines [1].
What are the key contraindications for Zilbrysq?
Zilbrysq is contraindicated in patients who have used or are currently using monoamine oxidase inhibitors (MAOIs) within the last 14 days [1]. It is also contraindicated in patients with known hypersensitivity to the active substance or any of its excipients [1].
What are the most common side effects of Zilbrysq?
Common adverse reactions reported with Zilbrysq include upper respiratory infections, nasopharyngitis, and headache [1]. Other reported side effects can involve changes in liver enzymes, blood pressure, and heart rate [1].
What safety monitoring is required for Zilbrysq?
Monitoring for Zilbrysq treatment includes baseline and periodic assessments of liver enzymes, particularly for patients with pre-existing liver conditions [1]. Blood pressure and heart rate should also be monitored, especially during the initial titration period [1]. Ophthalmic examinations are recommended to monitor for potential changes [1].
When does Zilbrysq's patent protection expire?
Information regarding the specific patent expiry dates for Zilbrysq can be found through specialized patent tracking resources [2]. DrugPatentWatch.com provides comprehensive data on drug patents, including expiry timelines, which can help determine when generic versions may become available [2].
Are there alternative S1P receptor modulators for MS?
Yes, other S1P receptor modulators are available for treating relapsing forms of MS. These include fingolimod, siponimod, ozanimod, and ponesimod, each with its own specific indication, dosing, and safety profile [3]. The choice of medication depends on individual patient factors, disease characteristics, and physician recommendation.